Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

A study projects AI funding will continue to increase, resulting in a massive number of new products during the next decade. 

Only about 30% of patients who underwent TAVR in Michigan participated in cardiac rehabilitation within 90 days after discharge.

New research is providing a broader understanding of how cardiovascular disease risk manifests following pregnancy. Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy.

Researchers hopes this first-in-class gene therapy, known as TN-201, can restore the patient’s MYBPC3 levels and eventually lead to disease reversal.

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects. 

Penn State Health developed a dashboard system to better understand radiology workflows and facilitate data sharing across the organization.